Uncategorized

  • Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board

    February 24, 2020

    Philadelphia, PA, February 24, 2020 – Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board of directors and scientific advisory board. Read full press release here.

    Read More
  • CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    May 8, 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its own U.S. pivotal trial for the treatment of elective percutaneous coronary intervention (ePCI) to complete enrolment before the end of 2018. Link to Press Release

    Read More